Search Result

Results for "

polymerases II

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (5) ADC Linker (1) Apoptosis (13) Bcl-2 Family (1) CDK (18) DNA/RNA Synthesis (19) Drug Derivative (1) Drug Isomer (2) Drug-Linker Conjugates for ADC (2) Endogenous Metabolite (3) HCV (1) Molecular Glues (1) Nucleoside Antimetabolite/Analog (3) Parasite (3) Phosphatase (3) Ras (1) Reference Standards (1) Reverse Transcriptase (3) SARS-CoV (3) Sirtuin (3) Topoisomerase (5)
By Research Areas:	Cancer (34) Cardiovascular Disease (3) Infection (4) Metabolic Disease (3)
Click Chemistry:	Azide (1)
Oligonucleotides:	Nucleotides and their Analogs (1) Nucleosides and their Analogs (1) C (1) G (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Antibodies

Click Chemistry

Oligonucleotides

Targets Recommended: Photosystem II CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16662

Oncrasin-1	DNA/RNA Synthesis Ras Apoptosis	Cancer
Oncrasin-1 is an RNA polymerase inhibitor. Oncrasin-1 suppresses the phosphorylation of the largest subunit of RNA polymerase II and the expression of intronless reporter genes in sensitive cells. Oncrasin-1 effectively kills various human lung cancer cells with K-Ras mutations. Oncrasin-1 leads to coaggregation of PKCι and splicing factors into megaspliceosomes. Oncrasin-1 induces malfunction in the RNA processing machinery. Oncrasin-1 is an anti-cancer agent and can therefore be studied in research for lung cancer .

HY-145072

BSJ-01-175	CDK	Cancer
BSJ-01-175 is a potent and selective CDK12/13 covalent inhibitor. BSJ-01-175 demonstrates exquisite selectivity, potent inhibition of RNA polymerase II phosphorylation, and downregulation of CDK12-targeted genes in cancer cells .

HY-131081

γ-Amanitin	DNA/RNA Synthesis ADC Cytotoxin	Cancer
γ-Amanitin an ADC cytotoxin and isolated from the mushroom. γ-Amanitin inhibits *RNA polymerase* II and disrupts synthesis of mRNA. γ-Amanitin shows similar effects to α-Amanitin and β-Amanitin. γ-Amanitin competitively binds to monoclonal antibody (mAb), with an IC₅₀** of 163.1 ng/mL. γ-Amanitin is toxic to a variety of cells .

HY-112626

CDK12-IN-2	CDK	Cancer
CDK12-IN-2 is a potent, selective and nanomolar CDK12 inhibitor (IC₅₀=52 nM) with good physicochemical properties. CDK12-IN-2 is also a strong CDK13 inhibitor due to CDK13 is the closest homologue of CDK12. CDK12-IN-2 shows excellent kinase selectivity for CDK12 over CDK2, 9, 8, and 7. CDK12-IN-2 inhibits the phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II. CDK12-IN-2 can be used an excellent chemical probe for functional studies of CDK12 .

HY-124552

Epolactaene	DNA/RNA Synthesis Topoisomerase	Others
Epolactaene is a potent Topoisomerase II and DNA Polymerase inhibitor with IC₅₀ values of 10, 25, 94 µM for Topoisomerase II, DNA Polymerase α, DNA Polymerase β, respectively .

HY-135780

3'-Deoxyuridine-5'-triphosphate 3'-dUTP	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Endogenous Metabolite	Metabolic Disease
3'-Deoxyuridine-5'-triphosphate (3'-dUTP) is a nucleotide analogue that inhibits DNA-dependent *RNA polymerases* I and II. 3'-Deoxyuridine-5'-triphosphate strongly and competitively inhibits the incorporations of UTP into RNA with a K_i** value of 2.0 μM .

HY-171786

CDK12-IN-8	CDK	Cancer
CDK12-IN-8 (Compound Cpd143) is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). CDK12-IN-8 inhibits CDK12-mediated phosphorylation of the C-terminal domain (CTD) serine 2 of RNA polymerase II, interfering with gene transcription elongation and DNA damage repair pathways. CDK12-IN-8 is promising for research of cancers with high CDK12 expression such as small cell lung cancer and triple-negative breast cancer .

HY-147917

*RNA polymerase* II-IN-2**	DNA/RNA Synthesis	Cancer
RNA polymerase II-IN-2 (compound 20iii) is a potent RNA polymerase II (Pol II) inhibitor with K_i value of 9.5 nM. RNA polymerase II-IN-2 has cytotoxicity against cancer cells, and exhibits 2 and 5 fold toxicity than α-amanitin against CHO and HEK293 .

HY-123034

CDKI-83	CDK Bcl-2 Family Apoptosis	Cancer
CDKI-83 is a potent CDK9 and CDK1 inhibitor with K_i values of 21 nM and 72 nM for CDK9/T1 and CDK1/B, respectively. CDKI-83 demonstrates effective anti-proliferative activity in human tumour cell lines with a GI₅₀<1 μM. CDKI-83 effectively induces apoptosis in A2780 human ovarian cancer cells. CDKI-83 reduces phosphorylation at Ser-2 of RNA polymerase II (RNAPII) by inhibiting cellular CDK9 activity, and down-regulates Mcl-1 and Bcl-2. CDKI-83 has the potential for anti-cancer research .

HY-115755

Thio-ITP 6-Thioinosine 5′-triphosphate; 6-Mercaptopurine-riboside-5'-triphosphate; 6-Thio-ITP	DNA/RNA Synthesis	Cancer
Thio-ITP (6-Thioinosine 5′-triphosphate) is an RNA polymerase activity competitive inhibitor. Thio-ITP has a high apparent affinity for the polymerases (RNA polymerase I K_i: 40.9 μM; RNA polymerase II K_i: 38.0 μM) .

HY-19610

α-Amanitin Maximum Cited Publications 37 Publications Verification α-Amatoxin	DNA/RNA Synthesis ADC Cytotoxin	Cancer
α-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting *RNA-polymerase* II**.

HY-131083

ε-Amanitin	DNA/RNA Synthesis ADC Cytotoxin	Cancer
ε-Amanitin, a cyclic peptide isolated from a variety of mushroom species, potently binds to and inhibits the activity of *RNA polymerase* II** .

HY-148231

Dideoxy-amanitin	DNA/RNA Synthesis ADC Cytotoxin	Cancer
Dideoxy-amanitin (compound 2), an α-Amanitin (HY-19610) derivative, is a potent and selective *RNA polymerase* II allosteric inhibitor with an IC₅₀** value of 74.2 nM .

HY-106556

Zorubicin Rubidazon; Rubidazone	DNA/RNA Synthesis Topoisomerase	Cancer
Zorubicin (Rubidazon) is a derivative of Daunorubicin (HY-13062A). Zorubicin interacts with topoisomerase II and inhibits DNA polymerases. Zorubicin can be used for the research of acute leukemias and sarcomas .

HY-16200

Ethynylcytidine 1 Publications Verification ECyD; TAS-106; 3'-C-Ethynylcytidine	DNA/RNA Synthesis Nucleoside Antimetabolite/Analog	Cancer
Ethynylcytidine (ECyD), a nucleoside analog and a potent inhibitor of RNA synthesis, inhibits RNA polymerases I, II and II. Ethynylcytidine has robust antitumor activity in a wide range of models of cancer . Ethynylcytidine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-126683

Mal-C6-α-Amanitin	Drug-Linker Conjugates for ADC	Cancer
Mal-C6-α-Amanitin is a agent-linker conjugate for ADC with potent antitumor activity by using α-Amanitin (an RNA polymerase II inhibitor), linked via the ADC linker Mal-C6.

HY-143584

AZ5576	CDK Apoptosis	Cancer
AZ5576 is a potent and highly selective CDK9 inhibitor (IC₅₀: <5 nM). AZ5576 inhibits the phosphorylation of RNA polymerase II at Ser2, thereby inhibiting transcriptional elongation. AZ5576 can be used for hematological Malignancy research .

HY-153244

MFH290	CDK	Cancer
MFH290 is a potent and highly selective cyclin-dependent kinase 12/13 (CDK12/13) covalent inhibitor. MFH290 forms a covalent bond with Cys-1039 of CDK12 and exhibits excellent kinome selectivity and inhibits the phosphorylation of serine-2 in the C-terminal domain (CTD) of RNA-polymerase II (Pol II). MFH290 is used for cancer research .

HY-P1933A

[pSer2, pSer5, pSer7]-CTD TFA	CDK	Cancer
[pSer2, pSer5, pSer7]-CTD (TFA), a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .

HY-125586

β-Amanitin	DNA/RNA Synthesis ADC Cytotoxin	Cancer
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic *RNA polymerase* II and III**. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-135780A

3'-Deoxyuridine-5'-triphosphate trisodium 3'-dUTP trisodium	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis Endogenous Metabolite	Metabolic Disease
3'-Deoxyuridine-5'-triphosphate trisodium (3'-dUTP trisodium) is a nucleotide analogue that inhibits DNA-dependent *RNA polymerases* I and II. 3'-Deoxyuridine-5'-triphosphate trisodium strongly and competitively inhibits the incorporations of UTP into RNA with a K_i** value of 2.0 μM .

HY-163856

CDK7-IN-30	Apoptosis CDK	Cancer
CDK7-IN-30 (Compound 22) is a CDK7 inhibitor (IC₅₀ = 7.21 nM) that effectively inhibits the phosphorylation of *RNA Polymerase* II and CDK2. CDK7-IN-30 CDK7-IN-30 can induce cell apoptosis** and has anti-cancer activity and can be used in cancer research .

HY-176484

CDK9-IN-39	CDK Apoptosis	Cancer
CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC₅₀ of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of *RNA polymerase* II** at Ser2 and can be used for study of colorectal cancer .

HY-172002

3'-O-Methylguanosine-5'-O-triphosphate sodium 3'-O-Methyl GTP sodium	Drug Derivative	Metabolic Disease
3'-O-Methylguanosine-5'-O-triphosphate (3'-O-Methyl GTP) sodium is a methylated derivative of Guanosine 5'-triphosphate (HY-W010737). 3'-O-Methylguanosine-5'-O-triphosphate has been used as a chain termination reagent in the preparation of early RNA polymerase II elongation intermediates.

HY-150641

CDK-IN-9	CDK Apoptosis DNA/RNA Synthesis Molecular Glues	Cancer
CDK-IN-9 (compound 24) is a potent CDK inhibitor, also as a molecular glue inducing an interaction between CDK12 and DDB1, with an IC₅₀ values of 4 nM for CDK2/E. CDK-IN-9 leads to polyubiquitination of cyclin K and its subsequent degradation. CDK-IN-9 induce apoptosis through dephosphorylation of retinoblastoma protein and *RNA polymerase* II** .

HY-143587

CDK7-IN-2	CDK	Cancer
CDK7-IN-2 is a potent inhibitor of CDK7. CDK7 is implicated in both temporal control of the cell cycle and transcriptional activity. CDK7 is implicated in the transcriptional initiation process by phosphorylation of Rbpl subunit of RNA Polymerase II (RNAPII). CDK7 has the potential for the research of cancer disease, in particular aggressive and hard- to-treat cancers (extracted from patent WO2019099298A1, compound 1) .

HY-10118

Filibuvir 2 Publications Verification	HCV DNA/RNA Synthesis	Infection
Filibuvir is an orally active, selective non-nucleoside inhibitor of the *HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase* (RdRp)**. Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC₅₀s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .

HY-130207

Oncrasin-72 NSC-743380	Endogenous Metabolite	Cancer
Oncrasin-72 (NSC-743380) is an RNA polymerase II inhibitor with activity in inhibiting growth and inducing cell death in human cancer cells. Oncrasin-72 exhibits antitumor activity through JNK activation and STAT3 inhibition. Analytical method development and validation for Oncrasin-72 is essential for quantifying its concentration in biological fluids for pharmacokinetic studies. This method was able to successfully quantify Oncrasin-72 in different dose groups when applied in rat plasma .

HY-103019E

Enitociclib BAY-1251152; VIP152	CDK Apoptosis DNA/RNA Synthesis	Others
Enitociclib (BAY-1251152; VIP152) is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of *RNA polymerase* Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1**. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-131089

MC-VC-PABC-C6-α-Amanitin	Drug-Linker Conjugates for ADC	Cancer
MC-VC-PABC-C6-α-Amanitin is an antibody agent conjugate consisting of an anticancer toxin alpha-Amanitin (HY-19610) and a monoclonal antibody MC-VC-PABC-C6. Among them, alpha-Amanitin is a potent inhibitor of *RNA polymerase* IIα. MC-VC-PABC-C6-α-Amanitin accurately targets HER2 receptors**, specifically recognizes HER2-positive tumor cells. It is widely used in breast cancer and gastric cancer research .

HY-103019

(+)-Enitociclib 2 Publications Verification (+)-BAY-1251152; (+)-VIP152; (S)-Enitociclib	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Cancer
(+)-Enitociclib ((+)-BAY-1251152) is the enantiomer of Enitociclib (HY-103019E) with (+) optical rotation. Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of *RNA polymerase* Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1**. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-103019A

(±)-Enitociclib (±)-BAY-1251152; (±)-VIP152	CDK Apoptosis DNA/RNA Synthesis	Cancer
(±)-Enitociclib ((±)-BAY-1251152) is the racemic mixture of Enitociclib (HY-103019E). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of *RNA polymerase* Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1**. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-103019B

(-)-Enitociclib (R)-Enitociclib; (-)-BAY-1251152; (-)-VIP152	Drug Isomer CDK Apoptosis DNA/RNA Synthesis	Cancer
(-)-Enitociclib ((R)-Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-). Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of *RNA polymerase* Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1**. Enitociclib has anti-proliferative activity targeting MYC ⁺ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies .

HY-B0879

Suramin	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) . Suramin is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin is a potent *SARS-CoV-2 RNA-dependent RNA polymerase* (RdRp) inhibitor .Suramin efficiently inhibits IP5K and is an antiparasitic**, anti-neoplastic and anti-angiogenic agent .

HY-101257

YKL-5-124 10+ Cited Publications	CDK	Cancer
YKL-5-124 is a potent, selective, irreversible and covalent CDK7 inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-173059

CDK12/13-IN-3	CDK	Cancer
CDK12/13-IN-3 (Compound 12b) is the orally active inhibitor for CDK that inhibits CDK12 and CDK13 with IC₅₀ of 107.4 nM and 79.4 nM. CDK12/13-IN-3 inhibits the phosphorylation of Ser2 on the CTD of RNA polymerase II, induces DNA damage, and downregulates the gene expression of DNA damage response (DDR). CDK12/13-IN-3 exhibits antiproliferative activity against multiple cancer cells with IC₅₀ of nanomolar levels. CDK12/13-IN-3 exhibits antitumor effect in mouse models, exhibits good pharmacokinetic properties with an oral bioavailability of 53.6% .

HY-101257B

YKL-5-124 TFA 10+ Cited Publications	CDK	Cancer
YKL-5-124 TFA is a potent, selective, irreversible and covalent CDK7 inhibitor with IC₅₀s of 53.5 nM and 9.7 nM for CDK7 and CDK7/Mat1/CycH, respectively. YKL-5-124 TFA is >100-fold greater selective for CDK7 than CDK9 and CDK2, and inactive against CDK12 and CDK13. YKL-5-124 TFA induces a strong cell-cycle arrest, inhibits E2F-driven gene expression, and exhibits little effect on RNA polymerase II phosphorylation status .

HY-B0879A

Suramin sodium salt 15+ Cited Publications Suramin hexasodium salt	Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin sodium salt is a potent *SARS-CoV-2 RNA-dependent RNA polymerase* (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic**, anti-neoplastic and anti-angiogenic agent .

HY-B0879AR

Suramin sodium salt (Standard) Suramin hexasodium salt (Standard)	Reference Standards Phosphatase Sirtuin Reverse Transcriptase Topoisomerase SARS-CoV Parasite Apoptosis	Infection Cardiovascular Disease Cancer
Suramin (sodium salt) (Standard) is the analytical standard of Suramin (sodium salt). This product is intended for research and analytical applications. Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatases (PTPases) inhibitor . Suramin sodium salt is a potent inhibitor of sirtuins: SirT1 (IC₅₀=297 nM), SirT2 (IC₅₀=1.15 μM), and SirT5 (IC₅₀=22 μM) . Suramin sodium salt is a competitive inhibitor of reverse transcriptase (DNA topoisomerase II: IC₅₀=5 μM) . Suramin sodium salt is a potent *SARS-CoV-2 RNA-dependent RNA polymerase* (RdRp) inhibitor . Suramin sodium salt efficiently inhibits IP5K and is an antiparasitic**, anti-neoplastic and anti-angiogenic agent .

HY-151829

Fmoc-L-Asn(EDA-N3)-OH	ADC Linker	Others
Fmoc-L-Asn(EDA-N3)-OH is a click chemistry reagent containing an azide group. This building block is reported in literature for the modification of Amanitin via Click Chemistry. Alpha-Amanitin is the deadliest member of the amatoxin peptide family produced by the death-cap mushroom A. phalloides. It is an orally available, rigid, bicyclic octapeptide and one of the most lethal known natural products (LD50 = 50-100 μg/kg) acting as highly selective allosteric inhibitor of the RNA polymerase II . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

Cat. No.	Product Name

HY-L090

Transcription Factor-Targeted Library	1,848 compounds
Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential. MCE offers a unique collection of 1,848 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.

Transcription Factor-Targeted Library

1,848 compounds

Transcription is the essential first step in the conversion of the genetic information in the DNA into protein and the major point at which gene expression is controlled. Transcription of protein-coding genes is accomplished by the multi-subunit enzyme RNA polymerase II and an ensemble of ancillary proteins, called transcription factors (TFs). Transcription factors play an important role in the long-term regulation of cell growth, differentiation and responses to environmental cues. Deregulated transcription factors contribute to the pathogenesis of a plethora of human diseases, ranging from diabetes, inflammatory disorders and cardiovascular disease to many cancers, and thus these proteins hold great therapeutic potential.

MCE offers a unique collection of 1,848 compounds with validated transcription factor targets modulating properties. MCE transcription factor-targeted compound library is an effective tool for researching transcription factors as drug targets as well as modulation of TFs for different therapeutic applications.

Cat. No.	Product Name	Target	Research Area

HY-125586

β-Amanitin	DNA/RNA Synthesis ADC Cytotoxin	Cancer
β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic *RNA polymerase* II and III**. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-P1933

[pSer2, pSer5, pSer7]-CTD	Peptides	Cancer
[pSer2, pSer5, pSer7]-CTD, a substrate for CDK7 (cyclin dependent protein kinase), is a phosphorylated polypeptide at ser2, ser5 and ser7 sites of RNA polymerase II carboxy-terminal domain (CTD) .